The respiratory tract’s microbial microflora plays a significant role in determining the severity of RSV infections and the ...

Influenza cases remain high nationally, and Atlantic Canada is bracing for peak of rising RSV cases despite declining rates ...

Research published in late 2024 in the journal JAMA Pediatrics found nirsevimab was more than 90 percent effective at preventing hospitalization for RSV, and 89 percent effective at preventing all ...

Health officials are urging older adults to get vaccinated against respiratory syncytial virus (RSV). NHS England announced ...

Michigan's largest health system urges patients to seek nonemergency care at sites other than its ERs amid a surge in flu, ...

The NHS is urging around 1.3 million older people who have not yet had the respiratory syncytial virus vaccine to get jabbed, as health service chiefs warn it is “not just a winter illness”. Invites ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

What are the symptoms of RSV and who is eligible for a vaccine? - RSV might at first seem like a cold but it can quickly ...

Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...